Grifols, S.A. (GRFS): Price and Financial Metrics


Grifols, S.A. (GRFS)

Today's Latest Price: $19.71 USD

0.41 (-2.04%)

Updated Jun 3 12:22pm

Add GRFS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

GRFS Stock Summary

  • With a market capitalization of $13,833,604,749, Grifols SA has a greater market value than 88.56% of US stocks.
  • Price to trailing twelve month operating cash flow for GRFS is currently 24.31, higher than 84.36% of US stocks with positive operating cash flow.
  • In terms of volatility of its share price, GRFS is more volatile than merely 5.99% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Grifols SA, a group of peers worth examining would be EMN, ALSN, CNHI, FMC, and ITGR.
  • GRFS's SEC filings can be seen here. And to visit Grifols SA's official web site, go to www.grifols.com.
GRFS Daily Price Range
GRFS 52-Week Price Range

GRFS Stock Price Chart More Charts


GRFS Price/Volume Stats

Current price $19.71 52-week high $25.73
Prev. close $20.12 52-week low $13.40
Day low $19.66 Volume 503,799
Day high $19.98 Avg. volume 1,031,270
50-day MA $19.99 Dividend yield 1.69%
200-day MA $21.46 Market Cap 13.55B

Grifols, S.A. (GRFS) Company Bio


Grifols, S.A. develops, manufactures, and distributes plasma derivative products in the United States, Canada, Spain, rest of the European Union, and internationally. It specializes in providing infusion solutions, nutrition products, medical devices, diagnostic instrumentation, and reagents for use in hospitals and clinics. The company operates through four segments: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The company was founded in 1940 and is based in Barcelona, Spain.


GRFS Latest News Stream


Event/TimeNews Detail
Loading, please wait...

GRFS Latest Social Stream


Loading social stream, please wait...

View Full GRFS Social Stream

Latest GRFS News From Around the Web

Below are the latest news stories about Grifols SA that investors may wish to consider to help them evaluate GRFS as an investment opportunity.

Racing Against Time, Medical Researchers, Life Science Companies and COVID-19 Survivors Launch National Campaign to Drive Blood Plasma Donation

A coalition of world-leading medical and research institutions, blood centers, life science companies, technology companies, philanthropic organizations, and COVID-19 survivor groups has come together to support the rapid development of potential new therapies for patients with COVID-19. Working together under the "The Fight Is In Us" campaign, the coalition is seeking to mobilize tens of thousands of people in the United States who have recovered from COVID-19 to donate their blood plasma, which contains vital antibodies that have fought off the disease and could now help others do the same.

Yahoo | May 26, 2020

Grifols Procleix Panther System with Automation Ready Technology (ART) receives FDA Approval

BARCELONA, Spain, May 7, 2020 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, today announced that it has received FDA approval for the Procleix…

PR Newswire | May 7, 2020

Repro-Med Systems (KRMD) Q1 2020 Earnings Call Transcript

Image source: The Motley Fool. Repro-Med Systems, or KORU Medical Systems (NASDAQ: KRMD)Q1 2020 Earnings CallMay 05, 2020, 9:00 a.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Greetings and welcome to the KORU Medical Systems reports first-quarter 2020 financial results.

Yahoo | May 7, 2020

Grifols launches new 3-mL (900-IU) vial for high-potency HyperRAB® (rabies immune globulin [human])

Grifols (MCE:GRF, MCE:GRF.P NASDAQ:GRFS), a leading global producer of plasma-derived medicines, today announced the launch of a new 3-mL (900-IU) vial for HyperRAB (rabies immune globulin [human]), a treatment for rabies postexposure prophylaxis.

Yahoo | April 28, 2020

GRFS vs. ZTS: Which Stock Should Value Investors Buy Now?

GRFS vs. ZTS: Which Stock Is the Better Value Option?

Yahoo | April 27, 2020

Read More 'GRFS' Stories Here

GRFS Price Returns

1-mo -0.61%
3-mo -11.81%
6-mo -14.19%
1-year 10.31%
3-year -4.19%
5-year 38.32%
YTD -15.37%
2019 28.71%
2018 -17.77%
2017 44.48%
2016 0.90%
2015 -2.72%

GRFS Dividends

Ex-Dividend DateTypePayout AmountChange
Loading, please wait...
View Full GRFS Dividend History

Continue Researching GRFS

Here are a few links from around the web to help you further your research on Grifols SA's stock as an investment opportunity:

Grifols SA (GRFS) Stock Price | Nasdaq
Grifols SA (GRFS) Stock Quote, History and News - Yahoo Finance
Grifols SA (GRFS) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9809 seconds.